Literature DB >> 3063288

Ventricular ectopic activity with diuretic therapy.

O B Holland1, L Kuhnert, J Pollard, M Padia, R J Anderson, G Blomqvist.   

Abstract

The arrhythmogenic potential of diuretic-induced hypokalemia in patients with uncomplicated hypertension has been controversial. Thirty-two hypertensive patients with previous diuretic-induced hypokalemia, normal 24-hour ambulatory ECG monitoring, and normal exercise testing were treated with 100 mg hydrochlorothiazide (HCTZ) daily (Group 1) to induce hypokalemia or with a combination of HCTZ with amiloride (Group 2) to attempt to maintain plasma potassium levels in the normal range during diuretic therapy. Those Group 1 patients (Group 1A) with increased ventricular ectopic activity (VEA) during HCTZ therapy were subsequently potassium-repleted with amiloride and with supplemental potassium chloride to evaluate the effect of these treatments on VEA. One Group 1 patient died suddenly after 12 days of HCTZ therapy. Autopsy findings suggested an arrhythmic death. Six Group 1 patients who had increased VEA with HCTZ treatment had reductions in VEA with amiloride or supplemental potassium chloride. Group 2 patients did not have a significant increase in VEA. Thus, diuretic therapy appears to cause VEA primarily by electrolyte changes that are induced.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3063288     DOI: 10.1093/ajh/1.4.380

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  3 in total

Review 1.  Drug-induced hypokalaemia. A cause for concern.

Authors:  G Isaac; O B Holland
Journal:  Drugs Aging       Date:  1992 Jan-Feb       Impact factor: 3.923

Review 2.  Diuretic-induced hypokalaemia and surgery: much ado about nothing?

Authors:  L J Restrick; N Huddy; B I Hoffbrand
Journal:  Postgrad Med J       Date:  1992-05       Impact factor: 2.401

Review 3.  Sudden cardiac death in patients with hypertension. An association with diuretics and beta-blockers?

Authors:  A W Hoes; D E Grobbee; J Lubsen
Journal:  Drug Saf       Date:  1997-04       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.